206 results on '"K. Fizazi"'
Search Results
2. Patient (pt) reported pain and health-related quality of life (HRQoL) by genomic loss of heterozygosity (gLOH) status in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1
- Author
-
F. Saad, A. Stenzl, N. Mehra, A. Stirling, V. Renard, J-P. Machiels, T. Dorff, M. Maruzzo, J. Nazari, H. Bhattacharyya, C. Healy, A. Niyazov, and K. Fizazi
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
3. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
- Author
-
K. Fizazi and S. Gillessen
- Subjects
Oncology ,Hematology - Published
- 2023
- Full Text
- View/download PDF
4. 173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
- Author
-
F. Parnis, B. Tombal, M. Hussain, F. Saad, K. Fizazi, C.N. Sternberg, E.D. Crawford, E. Kopyltsov, A. Rezazadeh Kalebasty, B.Y. Alekseev, A. Montesa Pino, D. Ye, F.J.S. Melo Cruz, T. Tammela, H. Suzuki, H. Joensuu, S. Thiele, R. Li, I. Kuss, and M. Smith
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
5. 1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial
- Author
-
A. Bernard-Tessier, M. Cancel, B. Tombal, G. Roubaud, J. Carles Galceran, A. Flechon, R.S. McDermott, S. Supiot, D.R. Berthold, R. Philippe, G. Kacso, G. Gravis Mescam, F. Calabrò, J.F. Berdah, A. Hasbini, F. Ricci, C. Hennequin, H. Ribault, S. Foulon, and K. Fizazi
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
6. 1374P Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
- Author
-
M.J. Morris, J.S. de Bono, J. Nagarajah, X.X. Wei, L.T. Nordquist, V.S. Koshkin, A. Vickers, O. Mirante, R. Ghouse, S.T. Tagawa, and K. Fizazi
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
7. 1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
- Author
-
Z. Guillaume, A. Bayle, C. Pobel, L. Lacroix, D. Vasseur, L. Albiges, E. Colomba, R. Flippot, N. Naoun, A. Patrikidou, V. Goldschmidt, P. Vuagnat, C. Massard, S. Ponce, K. Fizazi, Y. Loriot, C. Baldini, A. Italiano, and A. Bernard-Tessier
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
8. 1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
- Author
-
G. Gravis Mescam, X. Maldonado, G. Roubaud, R.S. McDermott, A. Flechon, B. Tombal, S. Supiot, D.R. Berthold, R. Philippe, G. Kacso, F. Calabrò, J.F. Berdah, A. Hasbini, M. Silva, A. Thiery-Vuillemin, A. Rodriguez-Vida, J.A. McCaffrey, H. Ribault, S. Foulon, and K. Fizazi
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
9. Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study
- Author
-
L. Antonelli, D. Ardizzone, P. Ravi, C. Sweeney, A. Bagrodia, M. Mego, A. Douglawi, T. Campanelli Palmer, S. Nazzani, P. Giannatempo, A. Franza, P. Paffenholz, R. Saoud, S. Eggener, M. Ho, N. Oswald, K. Olson, A. Tryakin, N. Naoun, C. Javaud, K. Fizazi, C. Cary, and C.D. Fankhauser
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
10. 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer
- Author
-
N. Menssouri, Y. Wesseling-Rozendaal, L. Poiraudeau, C. Helissey, L. Bigot, J. Sabio, T. Ibrahim, C. Nicotra, L. Tselikas, E. Colomba, P. Lavaud, B. Besse, J-Y. Scoazec, E. den Biezen, S. Neerken, K. Fizazi, D. Gautheret, P. van de Wiel, and Y. Loriot
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
11. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
- Author
-
K. Fizazi, M.R. Smith, M. Hussain, F. Saad, C. Sternberg, E.D. Crawford, J.B. Aragon-Ching, S. Thiele, S. Kapur, A.F. Mohamed, S. Srinivasan, R. Li, I. Kuss, H. Joensuu, and B. Tombal
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
12. 1422P Validation of the prognostic value of the early modeled longitudinal PSA kinetics (KELIM and KPROD) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with taxanes in FIRSTANA
- Author
-
A. Carrot, S. Oudard, O. Colomban, K. Fizazi, O. Sartor, G. Freyer, and B. You
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
13. 1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit
- Author
-
J.S. de Bono, E. Castro Marcos, D.A. Laird, K. Fizazi, T. Dorff, S. Zhao, I.M. van Oort, D. Gasparro, F. Calabrò, S. Pignata, L. Geczi, P. Barthelemy, D. Kilari, J.F. Hopkins, H-C. Chen, C.G. Healy, J. Chelliserry, G.V. Scagliotti, and N. Mehra
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
14. 1420P The pharmacokinetics and the pharmacodynamic effect of ODM-208, an inhibitor of cholesterol side-chain cleavage enzyme (CYP11A1)
- Author
-
A. Bernard-Tessier, P. Nykanen, T. Utriainen, N. Cook, P. Barthelemy, C. Baldini, N. Peters, T. Ikonen, P. Pohjanjousi, M. Karimaa, J. Malkki, P.T. Toivanen, C. Garratt, and K. Fizazi
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
15. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
- Author
-
P. Martin Romano, G. Roubaud, P. Lavaud, M. Cabart, A. Pages, D. Vasseur, E. Colomba, S. Cousin, M. Toulmonde, T. Grellety, Z. Castel Ajgal, R. Chabanon, A. Parpaleix, G. Buzzatti, K. Fizazi, C.A. Gomez-Roca, A. Italiano, Y. Loriot, and S. Postel-Vinay
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
16. 1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
- Author
-
K. Fizazi, A. Bernard-Tessier, P. Barthelemy, T. Utriainen, G. Roubaud, A. Flechon, J.C.M. van der Voet, G. Gravis Mescam, R. Ratta, R.H. Jones, O.A. Parikh, M.M.E. Tanner, C. Garratt, L. Nevalaita, P. Pohjanjousi, T. Ikonen, E.S. Antonarakis, and N. Cook
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
17. Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
- Author
-
Niven Mehra, A. Niyazov, M. Maruzzo, V. Renard, Celestia S. Higano, Howard Gurney, K. Fizazi, G.V. Scagliotti, H. Bhattacharyya, Bhakti Arondekar, Tanya B. Dorff, J-P. Machiels, Philippe Barthélémy, F. Saad, Cynthia G. Healy, A. Stenzl, J.S. de Bono, and A. Stirling
- Subjects
Health related quality of life ,Oncology ,medicine.medical_specialty ,business.industry ,Urology ,Castration resistant ,medicine.disease ,chemistry.chemical_compound ,Prostate cancer ,chemistry ,Internal medicine ,Talazoparib ,Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
18. Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
- Author
-
G.V. Scagliotti, Celestia S. Higano, Philippe Barthélémy, Tanya B. Dorff, M. Maruzzo, H. Bhattacharyya, K. Fizazi, A. Stenzl, V. Renard, J.S. de Bono, J-P. Machiels, F. Saad, Howard Gurney, A. Niyazov, Bhakti Arondekar, A. Stirling, Niven Mehra, and G.H. Cynthia
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Urology ,Castration resistant ,medicine.disease ,chemistry.chemical_compound ,Prostate cancer ,chemistry ,Internal medicine ,Medicine ,Talazoparib ,business ,Baseline (configuration management) ,Pain.status - Published
- 2021
- Full Text
- View/download PDF
19. Patient-reported pain by clinical outcome in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
- Author
-
C.H. Higano, H.B. Bhattacharyya, G.S. Scagliotti, A.S. Stirling, Niven Mehra, P.B. Barthelemy, H.G. Gurney, V. Renard, T.D. Dorff, J.M. Machiels, C.H. Healy, J.D.B. De Bono, M. Maruzzo, B.A. Arondekar, A.N. Niyazov, F. Saad, A. Stenzl, and K. Fizazi
- Subjects
Oncology ,medicine.medical_specialty ,chemistry.chemical_compound ,Prostate cancer ,chemistry ,business.industry ,Urology ,Internal medicine ,medicine ,Talazoparib ,Castration resistant ,medicine.disease ,business - Published
- 2021
- Full Text
- View/download PDF
20. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
- Author
-
A.A. Azad, J. Chakrabarti, Silvana Lanzalone, Joaquin Mateo, H.-C. Chen, F. Saad, N. Shore, K. Fizazi, A. Niyazov, Neeraj Agarwal, and Nobuaki Matsubara
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Urology ,Placebo ,Castration-sensitive prostate cancer ,law.invention ,Double blind ,chemistry.chemical_compound ,chemistry ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Enzalutamide ,Talazoparib ,In patient ,business ,Gene - Published
- 2021
- Full Text
- View/download PDF
21. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
- Author
-
Ladan Fazli, Laurent Désaubry, Daniel Compagno, Frédéric Commo, Nicolas Martin, Nader Al Nakouzi, Stéphanie Lerondel, Elaine Del Nery, Marine Garrido, Matthieu Bertrand, Anne Chauchereau, Nassif El Kalaany, Yohann Loriot, Stéphan Vagner, Jacques Camonis, K. Fizazi, Catherine Gaudin, Franck Perez, Martin E. Gleave, Alain Le Pape, Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Gustave Roussy (IGR), BioImaging Cell and Tissue Core Facility (PICT-IBiSA), Institut Curie [Paris], Centre d'Imagerie du Petit Animal (CIPA), Université d'Orléans (UO), Laboratoire d'Innovation Thérapeutique (LIT), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Stress génotoxiques et cancer, Université Paris-Sud - Paris 11 (UP11)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Radio-Fréquence et d'Intégration de Circuits (RFIC-Lab), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), University of British Columbia (UBC), Université Paris sciences et lettres (PSL), Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Structure Subcellulaire et Dynamique Cellulaire [Paris], Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Transgénèse et Archivage d'Animaux Modèles - Centre d'Imagerie du Petit Animal (TAAM-CIPA), Centre National de la Recherche Scientifique (CNRS), Centre d'Etude des Pathologies Respiratoires, Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Groupe Immunologie et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Substances naturelles/chimie moléculaire, Université Louis Pasteur - Strasbourg I-Ecole européenne de chimie, polymères et matériaux [Strasbourg]-Centre National de la Recherche Scientifique (CNRS), New York University School of Medicine (NYU), New York University School of Medicine, NYU System (NYU)-NYU System (NYU), Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR93-Université Paris-Sud - Paris 11 (UP11), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Université Grenoble Alpes (UGA), PSL Research University (PSL), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Dauphine-PSL-Institut Curie-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncologie génito-urinaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Université Paris-Sud - Paris 11 (UP11), and CHAUCHEREAU, Anne
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Taxane resistance ,Aucun ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,purl.org/becyt/ford/1 [https] ,Mice ,chemistry.chemical_compound ,Prostate cancer ,Eukaryotic initiation factor 4F ,0302 clinical medicine ,genetics ,RNA, Small Interfering ,ComputingMilieux_MISCELLANEOUS ,EIF4G ,Prostate Cancer ,3. Good health ,Gene Expression Regulation, Neoplastic ,FKBP7 ,Oncology ,Cabazitaxel ,030220 oncology & carcinogenesis ,Disease Progression ,Molecular chaperone ,Taxoids ,Translation initiation complex ,Chemoresistance ,Protein Binding ,medicine.drug ,Bridged-Ring Compounds ,Antineoplastic Agents ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Tacrolimus Binding Proteins ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,drug therapy ,metabolism ,pathology ,Cell Line, Tumor ,[SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology ,medicine ,Animals ,Humans ,Gene silencing ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Gene Silencing ,Chemioresistance ,purl.org/becyt/ford/1.6 [https] ,Peptidylprolyl isomerase ,business.industry ,Gene Expression Profiling ,Calcium-Binding Proteins ,Computational Biology ,Prostatic Neoplasms ,Cancer ,medicine.disease ,[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,Xenograft Model Antitumor Assays ,Disease Models, Animal ,030104 developmental biology ,Eukaryotic Initiation Factor-4F ,chemistry ,Drug Resistance, Neoplasm ,eIF4F ,Cancer research ,pharmacology ,Transcriptome ,business - Abstract
Purpose: Targeted therapies that use the signaling path-characterize the function of human FKBP7 and explore its ways involved in prostate cancer are required to overcome role in cancer. We discovered that FKBP7 was upregulated chemoresistance and improve treatment outcomes for men. in human prostate cancers and its expression correlated Molecular chaperones play a key role in the regulation of with the recurrence observed in patients receiving doce-protein homeostasis and are potential targets for overcom-taxel. FKBP7 silencing showed that FKBP7 is required to ing chemoresistance. maintain the growth of chemoresistant cell lines and Experimental Design: We established 4 chemoresistant chemoresistant tumors in mice. Mass spectrometry analysis prostate cancer cell lines and used image-based high-content revealed that FKBP7 interacts with eIF4G, a component of siRNA functional screening, based on gene-expression signa-the eIF4F translation initiation complex, to mediate the ture, to explore mechanisms of chemoresistance and identify survival of chemoresistant cells. Using small-molecule new potential targets with potential roles in taxane resistance. inhibitors of eIF4A, the RNA helicase component of The functional role of a new target was assessed by in vitro and eIF4F, we were able to kill docetaxel- and cabazitaxel-in vivo silencing, and mass spectrometry analysis was used to resistant cells. identify its downstream effectors. Conclusions: Targeting FKBP7 or the eIF4G-containing Results: We identified FKBP7, a prolyl-peptidyl isomer-eIF4F translation initiation complex could be novel thera-ase overexpressed in docetaxel-resistant and in cabazitaxel-peutic strategies to eradicate taxane-resistant prostate cancer resistant prostate cancer cells. This is the first study to cells. Fil: Garrido, Marine F.. Inserm; Francia Fil: Martin, Nicolas J.-P.. Inserm; Francia Fil: Bertrand, Matthieu. Inserm; Francia Fil: Gaudin, Catherine. Institut Anti-cancer Gustave Roussy; Francia Fil: Commo, Fred Eric. Inserm; Francia Fil: Kalaany, Nassif El. Inserm; Francia Fil: Al Nakouzi, Nader. University of British Columbia; Canadá Fil: Fazli, Ladan. University of British Columbia; Canadá Fil: Nery, Elaine Del. Université Pierre et Marie Curie; Francia Fil: Camonis, Jacques. Université Pierre et Marie Curie; Francia Fil: Perez, Franck. Université Pierre et Marie Curie; Francia Fil: Lerondel, Stéphanie. Centre National de la Recherche Scientifique; Francia Fil: Le Pape, Alain. Inserm; Francia Fil: Compagno, Daniel Georges. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; Argentina Fil: Gleave, Martin. University of British Columbia; Canadá Fil: Loriot, Yohann. Inserm; Francia Fil: Desaubry, Laurent. Centre National de la Recherche Scientifique; Francia Fil: Vagner, Stephan. Université Pierre et Marie Curie; Francia Fil: Fizazi, Karim. Institut Anti-cancer Gustave Roussy; Francia Fil: Chauchereau, Anne. Inserm; Francia
- Published
- 2019
- Full Text
- View/download PDF
22. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study
- Author
-
Nathalie Auger, K. Fizazi, Fanny Billiot, Aurélie Abou-Lovergne, Alexander Valent, Philippe Vielh, Yohann Loriot, Christophe Massard, Stéphanie Foulon, Sylvestre Le Moulec, Virginie Marty, Marianne Oulhen, and Françoise Farace
- Subjects
Male ,Research Report ,0301 basic medicine ,Oncology ,TMPRSS2-ERG translocation ,Pathology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,Biopsy ,Context (language use) ,circulating tumor cells ,Genetic Heterogeneity ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Circulating tumor cell ,androgen receptor ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,Prospective cohort study ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Prostate ,Cancer ,Middle Aged ,prostate cancer ,Neoplastic Cells, Circulating ,medicine.disease ,Prostatic Neoplasms, Castration-Resistant ,Phenotype ,030104 developmental biology ,Receptors, Androgen ,Cytopathology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,business ,Research Paper - Abstract
// Christophe Massard 1, 2, * , Marianne Oulhen 2, 3, * , Sylvestre Le Moulec 4 , Nathalie Auger 5 , Stephanie Foulon 6 , Aurelie Abou-Lovergne 1 , Fanny Billiot 2, 3 , Alexander Valent 5 , Virginie Marty 7 , Yohann Loriot 1, 2 , Karim Fizazi 1, 2 , Philippe Vielh 2, 3, 5, # , Francoise Farace 2, 3, # 1 Gustave Roussy, Universite Paris-Saclay, Department of Medicine, F-94805, Villejuif, France 2 INSERM, U981 “Identification of Molecular Predictors and New Targets for Cancer Treatment”, F-94805, Villejuif, France 3 Gustave Roussy, Universite Paris-Saclay, “Circulating Tumor Cells” Translational Platform, AMMICA CNRS UMS3655 – INSERM US23, F-94805, Villejuif, France 4 Hopital d’Instruction des Armees du Val de Grâce, Department of Oncology, F-75005, Paris, France 5 Gustave Roussy, Universite Paris-Saclay, Department of Biopathology, F-94805, Villejuif, France 6 Gustave Roussy, Universite Paris-Saclay, Department of Biostatistics and Epidemiology, F-94805, Villejuif, France 7 Gustave Roussy, Universite Paris-Saclay, “Histo Cytopathology” Translational Platform, AMMICA CNRS UMS3655 – INSERM US23, F-94805, Villejuif, France * These authors contributed equally to the study # These authors contributed equally to the study Correspondence to: Francoise Farace, email: francoise.farace@gustaveroussy.fr Keywords: prostate cancer, biopsy, circulating tumor cells, androgen receptor, TMPRSS2-ERG translocation Received: March 24, 2016 Accepted: June 17, 2016 Published: July 04, 2016 ABSTRACT Molecular characterization of cancer samples is hampered by tumor tissue availability in metastatic castration-resistant prostate cancer (mCRPC) patients. We reported the results of prospective PETRUS study of biomarker assessment in paired primary prostatic tumors, metastatic biopsies and circulating tumor cells (CTCs). Among 54 mCRPC patients enrolled, 38 (70%) had biopsies containing more than 50% tumour cells. 28 (52%) patients were analyzed for both tissue samples and CTCs. FISH for AR -amplification and TMPRSS2-ERG translocation were successful in 54% and 32% in metastatic biopsies and primary tumors, respectively. By comparing CellSearch and filtration (ISET)-enrichment combined to four color immunofluorescent staining, we showed that CellSearch and ISET isolated distinct subpopulations of CTCs: CTCs undergoing epithelial-to-mesenchymal transition, CTC clusters and large CTCs with cytomorphological characteristics but no detectable markers were isolated using ISET. Epithelial CTCs detected by the CellSearch were mostly lost during the ISET-filtration. AR -amplification was detected in CellSearch-captured CTCs, but not in ISET-enriched CTCs which harbor exclusively AR gain of copies. Eighty-eight percent concordance for ERG -rearrangement was observed between metastatic biopsies and CTCs even if additional ERG -alteration patterns were detected in ISET-enriched CTCs indicating a higher heterogeneity in CTCs. Molecular screening of metastatic biopsies is achievable in a multicenter context. Our data indicate that CTCs detected by the CellSearch and the ISET-filtration systems are not only phenotypically but also genetically different. Close attention must be paid to CTC characterization since neither approach tested here fully reflects the tremendous phenotypic and genetic heterogeneity present in CTCs from mCRPC patients.
- Published
- 2016
- Full Text
- View/download PDF
23. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
- Author
-
C L, Vale, D J, Fisher, I R, White, J R, Carpenter, S, Burdett, N W, Clarke, K, Fizazi, G, Gravis, N D, James, M D, Mason, M K B, Parmar, L H, Rydzewska, C J, Sweeney, M R, Spears, M R, Sydes, and J F, Tierney
- Subjects
Male ,Prednisolone ,Network Meta-Analysis ,Abiraterone Acetate ,Prostatic Neoplasms ,Androgen Antagonists ,Docetaxel ,Original Articles ,Prostate-Specific Antigen ,prostate cancer ,Zoledronic Acid ,Disease-Free Survival ,Urogenital Tumors ,systematic review ,abiraterone ,Antineoplastic Combined Chemotherapy Protocols ,Disease Progression ,androgen-deprivation therapy ,Humans ,Prednisone - Abstract
Background Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies. Methods Overall survival (OS) and failure-free survival data from completed Systemic Treatment Options for Cancer of the Prostate reviews of Doc, ZA and AAP and from recent trials of ZA and Cel contributed to this comprehensive AD-NMA. The primary outcome was OS. Correlations between treatment comparisons within one multi-arm, multi-stage trial were estimated from control-arm event counts. Network consistency and a common heterogeneity variance were assumed. Results We identified 10 completed trials which had closed to recruitment, and one trial in which recruitment was ongoing, as eligible for inclusion. Results are based on six trials including 6204 men (97% of men randomised in all completed trials). Network estimates of effects on OS were consistent with reported comparisons with ADT alone for AAP [hazard ration (HR) = 0.61, 95% confidence interval (CI) 0.53–0.71], Doc (HR = 0.77, 95% CI 0.68–0.87), ZA + Cel (HR = 0.78, 95% CI 0.62–0.97), ZA + Doc (HR = 0.79, 95% CI 0.66–0.94), Cel (HR = 0.94 95% CI 0.75–1.17) and ZA (HR = 0.90 95% CI 0.79–1.03). The effect of ZA + Cel is consistent with the additive effects of the individual treatments. Results suggest that AAP has the highest probability of being the most effective treatment both for OS (94% probability) and failure-free survival (100% probability). Doc was the second-best treatment of OS (35% probability). Conclusions Uniquely, we have included all available results and appropriately accounted for inclusion of multi-arm, multi-stage trials in this AD-NMA. Our results support the use of AAP or Doc with ADT in men with metastatic hormone-naive prostate cancer. AAP appears to be the most effective treatment, but it is not clear to what extent and whether this is due to a true increased benefit with AAP or the variable features of the individual trials. To fully account for patient variability across trials, changes in prognosis or treatment effects over time and the potential impact of treatment on progression, a network meta-analysis based on individual participant data is in development.
- Published
- 2018
24. Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
- Author
-
V. Iebba, L. Albiges, L. Alla, E. Colomba, C. Alves Costa Silva, N. Pons, G. Baciarello, E. Le Chatelier, K. Fizazi, B. Routy, B. Escudier, L. Zitvogel, and L. Derosa
- Subjects
Oncology ,medicine.medical_specialty ,biology ,business.industry ,medicine.drug_class ,Sunitinib ,Antibiotics ,Hematology ,Gut flora ,medicine.disease ,biology.organism_classification ,Axitinib ,Renal cell carcinoma ,Internal medicine ,Medicine ,Nivolumab ,business ,Tyrosine kinase ,Akkermansia muciniphila ,medicine.drug - Abstract
Background Evidence suggests that ATB and gut microbiota composition are associated to anti-PD-1 outcomes in RCC patients. Network analysis of the gut microbiota represents a novel tool to determine “guilds” of bacterial communities. Methods Here, we investigated guilds’ relationships with prior exposure to ATB, TKI [axitinib (axi), sunitinib (suni) or other] and clinical outcomes of RCC patients treated with nivolumab (nivo). Results Considering prior exposure to ATB (n = 11, 22%), axi (n = 13, 19%), suni (n = 49, 71%) or other TKI (n = 20, 29%), n = 36 (52%) patients were NR and 33 (48%) R to nivo. Cross-validation of overall fecal microbiota composition stratified RCC patients with different predictive power (ATB=84%; axi=81%; suni=69%; outcome=49%). Network analysis revealed six guilds (G1 to G6). G1-G2 behaved in an opposite way and topologically separated by negative correlations. G1-G2 were both related to NR, while G1 was dominated by species related to ATB. Conversely G2 was mainly represented by species related to no ATB (X2=8.98, P = 0.0027) and more susceptible to prior TKI exposure (where axi and suni behaved in an opposite way) compared to the other guilds (X2=10.68, P = 0.0011). G4 was mainly inhabited by species related to other TKI (no axi and no suni). Random forest analysis found definite bacterial species able to drive the stratification into guilds of the global RCC network, such as Akkermansia muciniphila for R and Dorea formicigenerans for no ATB. Conclusions We show that ATB and suni are the most powerful external features able to drive fecal microbiota compositional shifts in RCC patients treated with nivo. Analysis of the gut microbiota using bacterial communities guilds provides a novel theranostic approach to stratify RCC patients. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure L. Albiges: Honoraria (self): Novartis, BMS, Amgen, Ipsen, Roche, Pfizer, Astellas, Merck. K. Fizazi: Advisory / Consultancy: Participation to advisory boards/honorarium for: Astellas, AAA, Bayer, Clovis, Curevac, Incyte, Janssen, MSD, Orion, Sanofi. B. Escudier: Advisory / Consultancy: IPSEN, BMS, AZ, Novartis, Roche, Oncorena. L. Zitvogel: Advisory / Consultancy: BMS, AstraZeneca,; Research grant / Funding (self): Incyte, GSK, Transgene, Innovate Biopharma, Pilege; Advisory / Consultancy: Everimmune. All other authors have declared no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
25. Additional file 1: Figure S1. of Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
- Author
-
C. Lindsay, S. Le Moulec, F. Billiot, Y. Loriot, M. Ngo-Camus, P. Vielh, K. Fizazi, C. Massard, and F. Farace
- Subjects
macromolecular substances - Abstract
Validation of vimentin and Ki67 staining using the CellSearch platform. Figure S2. Prognostic impact of total CTC in two cohorts of patients with CRPC. Figure S3. Prognostic impact of vimentin/Ki67 CTC proportions and their presence in the unfavourable subgroup. Important validation work performed to justify subsequent experiments and conclusions. Figure S1. details the optimisation on CellSearch of Vimentin and Ki67 antibodies. Figure S2. shows that prognostic analysis of total CTC (regardless of vimentin and Ki67 measurements) is consistent with previous reports. Figure S3. shows that there is no prognostic significance of KI67 or vimentin CTC in the unfavourable prognosis subgroup, and that proportion of Ki67- or vimentin-CTC is less prognostically important than their presence or absence. (PDF 1030 kb)
- Published
- 2016
- Full Text
- View/download PDF
26. Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials
- Author
-
S. Guillonneau, Ayse Ozatilgan, Oliver Sartor, Mario A. Eisenberger, Denise Bury, Stéphane Oudard, A. Thiery Vuillemin, K. Fizazi, and J.S. de Bono
- Subjects
Oncology ,Health related quality of life ,medicine.medical_specialty ,Post hoc ,business.industry ,Hematology ,Castration resistant ,medicine.disease ,Prostate cancer ,Cabazitaxel ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Published
- 2018
- Full Text
- View/download PDF
27. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Author
-
H-J, Schmoll, K, Jordan, R, Huddart, M P Laguna, Pes, A, Horwich, K, Fizazi, V, Kataja, L, Wood, Cancer Center Amsterdam, Amsterdam Public Health, and Urology
- Subjects
Male ,Salvage Therapy ,L-Lactate Dehydrogenase ,Radiotherapy ,Biopsy ,Incidence ,Medizin ,Hematology ,Combined Modality Therapy ,Risk Assessment ,Seminoma ,Europe ,Treatment Outcome ,Oncology ,Testicular Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Secondary Prevention ,Humans ,Chorionic Gonadotropin, beta Subunit, Human ,alpha-Fetoproteins ,Neoplasm Metastasis ,Orchiectomy ,Carcinoma in Situ ,Follow-Up Studies ,Neoplasm Staging - Published
- 2010
- Full Text
- View/download PDF
28. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
- Author
-
H-J, Schmoll, K, Jordan, R, Huddart, M P, Laguna, A, Horwich, K, Fizazi, V, Kataja, Cancer Center Amsterdam, Amsterdam Public Health, and Urology
- Subjects
Europe ,Male ,Treatment Outcome ,Health Planning Guidelines ,Testicular Neoplasms ,Oncology ,Humans ,Hematology ,Societies, Medical ,Follow-Up Studies ,Seminoma - Published
- 2009
- Full Text
- View/download PDF
29. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
- Author
-
N. Nicolai, O. Leiva, Johnathan K Joffe, O. Klepp, P. Walz, Rolf Mueller, M. de Wit, S. Clemm, S. D. Fossa, Niels E. Skakkebæk, Gedske Daugaard, Robert Huddart, S. Tjulandin, M. Kuczyk, S. Krege, M. D. Mason, G. Kaiser, X. Garcia del Muro, László Kisbenedek, Gosse O N Oosterhof, O. Rick, Wolfgang Hoeltl, S. Kliesch, H. von der Maase, M. Bamberg, A. Gerl, N. Aass, Christian Kollmannsberger, G. Pizzocaro, M. Hartmann, L. Weissbach, O. Pont, U. Studer, P. Albers, M.P. Laguna, V. Loy, R. Souchon, H.-J. Schmoll, J. P. Droz, P.H.M. de Mulder, Heinz Schmidberger, Jörg Beyer, K. Fizazi, Tobias Pottek, J. Classen, G. M. Mead, Alan Horwich, L. Paz Ares, C. Bokemeyer, W. Jones, Eva Winter, T. Oliver, H. G. Derigs, J. R. Germa-Lluch, Felix Sedlmayer, István Bodrogi, Stefan Weinknecht, M. Flasshove, A. Heidenreich, F. Algaba, R. de Wit, S. Culine, K. U. Koehrmann, C. Wittekind, J. T. Hartmann, K. P. Dieckmann, W. Siegert, G. Rosti, and Medical Oncology
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Salvage therapy ,Disease ,SDG 3 - Good Health and Well-being ,Testicular Neoplasms ,Interventional oncology [UMCN 1.5] ,Internal medicine ,Testis ,medicine ,Humans ,Stage (cooking) ,Testicular cancer ,Neoplasm Staging ,Salvage Therapy ,Chemotherapy ,business.industry ,Hematology ,Seminoma ,Guideline ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Magnetic Resonance Imaging ,Chemotherapy regimen ,Surgery ,Europe ,Tomography, X-Ray Computed ,business ,Orchiectomy - Abstract
Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of > or = 99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception
- Published
- 2004
- Full Text
- View/download PDF
30. 2513 New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
- Author
-
B. Escudier, Laurence Albiges, Lisa Derosa, Y. Loriot, Laura Galli, A. Guida, K. Fizazi, and Christophe Massard
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Second line ,Renal cell carcinoma ,business.industry ,Internal medicine ,medicine.medical_treatment ,medicine ,medicine.disease ,business ,Targeted therapy - Published
- 2015
- Full Text
- View/download PDF
31. Prostate cancer: ESMO Consensus Conference Guidelines 2012
- Author
-
A. Horwich, J. Hugosson, T. de Reijke, T. Wiegel, K. Fizazi, V. Kataja, Chris Parker, Joaquim Bellmunt, Dominik Berthold, Anna Bill-Axelson, Sigrid Carlsson, Gedske Daugaard, Gert De Meerleer, Theo de Reijke, David Dearnaley, Karim Fizazi, Valérie Fonteyne, Silke Gillessen, Daniel Heinrich, Alan Horwich, Jonas Hugosson, Vesa Kataja, Maciej Kwiatkowski, Sten Nilsson, Anwar Padhani, Christos Papandreou, Monique Roobol, Avishay Sella, Riccardo Valdagni, Theo Van der Kwast, Paul Verhagen, Thomas Wiegel, CCA -Cancer Center Amsterdam, and Urology
- Subjects
Gynecology ,Male ,medicine.medical_specialty ,Prostate biopsy ,medicine.diagnostic_test ,Antineoplastic Agents, Hormonal ,business.industry ,MEDLINE ,Prostatic Neoplasms ,Hematology ,Scientific literature ,Prostate-Specific Antigen ,Sipuleucel-T ,Oncology ,Cabazitaxel ,Family medicine ,Localized disease ,Cancer screening ,medicine ,Transrectal ultrasonography ,Humans ,Lymph Nodes ,business ,medicine.drug ,Digital Rectal Examination - Abstract
The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.
- Published
- 2013
32. Etude prospective de la symptomatologie clinique précoce après irradiation corporelle totale thérapeutique de 2 Gy
- Author
-
Jean-Marc Cosset, Alain Fourquet, P. Jammet, M. P. Chaillet, and K. Fizazi
- Subjects
Abdominal pain ,medicine.medical_specialty ,Performance status ,Renewable Energy, Sustainability and the Environment ,Nausea ,business.industry ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Anorexia ,Total body irradiation ,Granisetron ,Parotid gland ,Surgery ,medicine.anatomical_structure ,Nuclear Energy and Engineering ,Anesthesia ,medicine ,Vomiting ,medicine.symptom ,Safety, Risk, Reliability and Quality ,business ,Waste Management and Disposal ,medicine.drug - Abstract
Early human tolerance following total body irradiation (TBI) according to the dose received is still poorly known. Thirteen selected patients were prospecti vely evaluated for clinical side effects during the first 10 hours following a 2 Gy TBI prior to bone marrow transplantation. All of them but one were treated for haematological malignancies and were in clinical remission at the date of TBI. There were 10 males and 3 females, with a median age of 43 y (range 16-61) and a good performance status (WHO 0-1). They received granisetron (3 mg) injec ted intravenously 1 h before the time of TBI in order to prevent nausea and vomiting. The main symptoms consisted in drowsiness (69 %), headache (62 %), xerostomia (62 %), nausea and vomiting (46 %), anorexia (38 %), parotid gland pain (23 %) and abdominal pain (8 %). Their intensity was always moderate, except for 2 patients who experimented severe vomiting. The incidence rate and the time-course of the symptoms of the prodromal phase may proved to be helpful for early clinical evaluation and triage of victims of an accidental irra diation. In particular, absence of fever at the 6 th h after TBI supports the assumption of an estimated exposure dose below 2 Gy.
- Published
- 1995
- Full Text
- View/download PDF
33. Germ-cell tumor survivors: the price for cure
- Author
-
K. Fizazi, I. Chen, and Christopher J. Logothetis
- Subjects
Oncology ,medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Internal medicine ,medicine ,Hematology ,business ,Germ cell - Published
- 2002
- Full Text
- View/download PDF
34. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
- Author
-
M, Bachner, Y, Loriot, M, Gross-Goupil, P A, Zucali, A, Horwich, J-R, Germa-Lluch, C, Kollmannsberger, F, Stoiber, A, Fléchon, K, Oechsle, S, Gillessen, J, Oldenburg, G, Cohn-Cedermark, G, Daugaard, F, Morelli, A, Sella, S, Harland, M, Kerst, J, Gampe, C, Dittrich, K, Fizazi, and M, De Santis
- Subjects
Male ,Testicular Neoplasms ,Positron-Emission Tomography ,Glucose-6-Phosphate ,Humans ,Radiopharmaceuticals ,Sensitivity and Specificity ,Retrospective Studies ,Seminoma - Abstract
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) has been recommended in international guidelines in the evaluation of postchemotherapy seminoma residuals. Our trial was designed to validate these recommendations in a larger group of patients.FDG-PET studies in patients with metastatic seminoma and residual masses after platinum-containing chemotherapy were correlated with either the histology of the resected lesion(s) or the clinical outcome.One hundred and seventy seven FDG-PET results were contributed. Of 127 eligible PET studies, 69% were true negative, 11% true positive, 6% false negative, and 15% false positive. We compared PET scans carried out before and after a cut-off level of 6 weeks after the end of the last chemotherapy cycle. PET sensitivity, specificity, negative predictive value (NPV), and positive predictive value were 50%, 77%, 91%, and 25%, respectively, before the cut-off and 82%, 90%, 95%, and 69% after the cut-off. PET accuracy significantly improved from 73% before to 88% after the cut-off (P=0.032).Our study confirms the high specificity, sensitivity, and NPV of FDG-PET for evaluating postchemotherapy seminoma residuals. When carried out at an adequate time point, FDG-PET remains a valuable tool for clinical decision-making in this clinical setting and spares patients unnecessary therapy.
- Published
- 2011
35. Oxaliplatin in non-seminomatous germ-cell tumors
- Author
-
S. Culine, K. Fizazi, and I. Chen
- Subjects
Male ,CD30 ,Organoplatinum Compounds ,business.industry ,Antineoplastic Agents ,Hematology ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Prognosis ,Oxaliplatin ,Text mining ,Oncology ,Testicular Neoplasms ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Cancer research ,Humans ,Germ cell tumors ,business ,medicine.drug - Published
- 2004
36. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial
- Author
-
Kim Anh Do, Christopher J. Logothetis, Laury Finn, K. Fizazi, X. Wang, and Robert J. Amato
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,Time Factors ,Cyclophosphamide ,Adolescent ,medicine.medical_treatment ,Urology ,Vinblastine ,chemistry.chemical_compound ,Bleomycin ,Testicular Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Mucositis ,Humans ,Survival rate ,Survival analysis ,Neoplasm Staging ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Hematology ,Middle Aged ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Survival Analysis ,Nitrogen mustard ,Surgery ,Regimen ,Oncology ,chemistry ,Doxorubicin ,Cisplatin ,business ,medicine.drug - Abstract
Background: This prospective randomized clinical trial was designed to compare the efficacy of low-dose regimen of cisplatin, doxorubicin and cyclophosphamide alternated with vinblastine and hleomycin (CISCA/VB) with the original CISCA/VB regimen in patients with disseminated non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable outcome. Patients and methods: One hundred and twenty-five patients with disseminated NSGCT and a predicted favorable outcome according to the M.D. Anderson Cancer Center classification [testicular primary and human chorionic gonadotropin (hCG) serum level
- Published
- 2002
37. PCN128 EQ-5D Utility Index in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Progression During or After First-Line Docetaxel Therapy
- Author
-
C. Laizet, K. Fizazi, Nicholas D. James, Mario A. Eisenberger, F. Joulain, and Axel Heidenreich
- Subjects
Oncology ,medicine.medical_specialty ,Index (economics) ,business.industry ,First line ,Health Policy ,Public Health, Environmental and Occupational Health ,Castration resistant ,medicine.disease ,Prostate cancer ,Docetaxel ,EQ-5D ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Published
- 2011
- Full Text
- View/download PDF
38. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway
- Author
-
J, Yang, K, Fizazi, S, Peleg, C R, Sikes, A K, Raymond, N, Jamal, M, Hu, M, Olive, L A, Martinez, C G, Wood, C J, Logothetis, G, Karsenty, and N M, Navone
- Subjects
Male ,Osteocalcin ,Transplantation, Heterologous ,Cell Count ,Core Binding Factor Alpha 1 Subunit ,Mice, SCID ,Bone and Bones ,Mice ,Tumor Cells, Cultured ,Animals ,Humans ,Cells, Cultured ,Osteoblasts ,Prostatic Neoplasms ,Cell Differentiation ,Prostate-Specific Antigen ,Blotting, Northern ,Coculture Techniques ,Neoplasm Proteins ,Gene Expression Regulation ,Culture Media, Conditioned ,RNA ,Cell Division ,Neoplasm Transplantation ,Signal Transduction ,Transcription Factors - Abstract
Metastases from prostatic adenocarcinoma (prostate cancer) are characterized by their predilection for bone and typical osteoblastic features. An in vitro model of bone metastases from prostate cancer was developed using a bicompartment coculture system of mouse osteoblasts and human prostate cancer cells. In this model, the bone-derived prostate cancer cell lines MDA PCa 2a and MDA PCa 2b induced a specific and reproducible increase in osteoblast proliferation. Moreover, these cells were able to induce osteoblast differentiation, as assessed by increased alkaline phosphatase activity, Osteocalcin expression, and calcified matrix formation. This osteoblastic reaction was confirmed in vivo by intrafemoral injection of MDA PCa 2b cells into severe combined immunodeficiency disease mice. In contrast, the highly undifferentiated, bone-derived human prostate cancer cell line PC3 did not produce an osteoblastic reaction in vitro and induced osteolytic lesions in vivo. The osteoblast differentiation induced by MDA PCa 2b cells was associated with up-regulation of the osteoblast-specific transcriptor factor Cbfa1. Moreover, treatment of osteoblasts with conditioned medium obtained from MDA PCa 2b cells resulted in up-regulation of Cbfa1 and Osteocalcin expression. In support of the differentiation studies, a microarray analysis showed that primary mouse osteoblasts grown in the presence of MDA PCa 2b cells showed a shift in the pattern of gene expression with an increase in mRNA-encoding Procollagen type I and Osteopontin and a decrease in mRNA-encoding proteins associated with myoblast differentiation, namely myoglobin and myosin light-chain 2. Taken together, these findings suggest that the bone-derived prostate cancer cells MDA PCa 2a and MDA PCa 2b promote differentiation of osteoblast precursors to an osteoblastic phenotype through a Cbfa1-dependent pathway. These results also established that soluble factors produced by prostate cancer cells can induce expression of osteoblast-specific genes. This in vitro model provides a valuable system to isolate molecules secreted by prostate cancer cells that favor osteoblast differentiation. Moreover, it allows to screen for therapeutic agents blocking the osteoblast response to prostate cancer.
- Published
- 2001
39. 4525 POSTER Self evaluation of side-effects of patients treated sequentially with sunitinib and sorafenib in kidney cancer
- Author
-
Bernard Escudier, K. Fizazi, Christophe Massard, A. Plantade, and S. Leborgne
- Subjects
Oncology ,Sorafenib ,Cancer Research ,medicine.medical_specialty ,Sunitinib ,business.industry ,medicine.disease ,Internal medicine ,Self evaluation ,medicine ,business ,Kidney cancer ,medicine.drug - Published
- 2007
- Full Text
- View/download PDF
40. K. Syrigos (ed). Prostate Cancer: Biology, Diagnosis and Management
- Author
-
K. Fizazi
- Subjects
Oncology ,medicine.medical_specialty ,Prostate cancer ,business.industry ,Internal medicine ,medicine ,Hematology ,medicine.disease ,business - Published
- 2003
- Full Text
- View/download PDF
41. Book review
- Author
-
K. Fizazi
- Subjects
Oncology ,Hematology - Published
- 2001
- Full Text
- View/download PDF
42. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
- Author
-
K Fizazi and L Morat
- Subjects
- *
PROSTATE cancer , *TELOMERASE , *BLOOD , *EPITHELIAL cells , *ANTIGENS - Abstract
Background: Circulating tumor cells (CTCs) cannot be readily detected with currently available methods in the majority of patients with prostate cancer. Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer.Patients and methods: Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll–Hypaque. Immunomagnetic beads coated with an epithelial cell-specific antigen antibody (BerEP4) were used to harvest epithelial cells from PBMCs. Telomerase activity was detected in harvested epithelial cells using the telomerase–PCR–enzyme-linked immunosorbent assay method.Results: Blood samples from 107 patients with prostate cancer were studied. CTCs were detected in 19 of 24 (79%) patients with advanced prostate cancer. In contrast, CTCs were not detected in blood samples from 22 healthy male volunteers. CTCs were even identified in patients with an undetectable (<0.1 ng/ml) serum prostate-specific antigen (PSA). CTCs were detected in 55 of 70 (79%) patients with localized prostate cancer before radical prostatectomy (n = 30) or brachytherapy (n = 40). CTCs were also detected in 3 of 13 patients (23%) with an undetectable serum PSA measured at least 1 year after radical prostatectomy, which is consistent with the expected relapse rate in this setting.Conclusion: CTCs can be detected using telomerase activity in a large majority and a wide variety of patients with prostate cancer, including those with localized disease. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
43. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
- Author
-
K. Fizazi, J. Oldenburg, A. Dunant, I. Chen, R. Salvioni, J. T. Hartmann, M. De Santis, G. Daugaard, A. Flechon, U. de Giorgi, S. Tjulandin, H. J. Schmoll, J. Bouzy, S. D. Fossa, and G. Fromont
- Subjects
- *
TUMORS , *GERM cells , *PROGNOSIS , *DRUG therapy , *SURGICAL excision - Abstract
Background: The purpose of this study was to validate a prognostic index [surgical complete response 1 (sCR1)] in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT). Patients and methods: Data and specimens from 61 patients with normalized tumor markers and postchemotherapy viable nonteratomatous NSGCT treated in 13 institutions were collected. Results: With a median follow-up of 5.4 years, the 5-year progression-free survival (PFS) rate was 65%; the 5-year overall survival (OS) rate was 72%. Favorable PFS was predicted by a complete resection, P = 0.002) (as compared with 90%, 76%, and 41% in the original sCR1 study). The 5-year OS rate was 90%, 86%, and 52%, respectively (P = 0.009) (as compared with 100%, 83%, and 51% in the original sCR1 study). Postoperative chemotherapy did not appear to improve OS compared with surveillance and treatment only at relapse. Conclusion: In patients with postchemotherapy viable NSGCT, a complete resection of residual masses should be rigorously pursued. These data validate the sCR1 prognostic index. Given their excellent outcome, patients in the favorable group may not require postoperative chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
44. The quest for the bony Grail of detecting circulating tumour cells in patients with prostate cancer.
- Author
-
C. Massard, A. Chauchereau, and K. Fizazi
- Published
- 2009
- Full Text
- View/download PDF
45. Carcinomas of an unknown primary site: a curable disease?
- Author
-
A. Levy, C. Massard, M. Gross-Goupil, and K. Fizazi
- Published
- 2008
- Full Text
- View/download PDF
46. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
- Author
-
C. Theodore, C. Chevreau, Y. Yataqhene, K. Fizazi, J. -P. Delord, J. -P. Lotz, L. Geoffrois, P. Kerbrat, V. Bui, and A. Flechon
- Subjects
- *
OXALIPLATIN , *PACLITAXEL , *CISPLATIN , *GERM cell tumors , *TUMORS , *PATIENTS , *PROGNOSIS - Abstract
Background: The aim of this study is to determine feasibility and efficacy of the combination regimen oxaliplatin and paclitaxel in patients with cisplatin (CDDP)-refractory germ-cell tumors (GCT). Patients and methods: Patients with either a cisplatin absolute-refractory GCT defined as progressive disease (PD) during or within 1 month of CDDP administration or with a poor prognosis relapse, defined as PD between the second and the sixth month after CDDP administration, were treated with a combination of oxaliplatin (130 mg/m2) and paclitaxel (175 mg/m2) administered every 21 days. Primary end point was efficacy. Results: Twenty-seven patients were included. Patients were pretreated with a median of two lines of cisplatin-based chemotherapy (range 1–5). Sixteen patients were absolute refractory. Five patients had relapsed after high-dose chemotherapy plus stem-cell support. There were no complete responses but there was one marker-positive partial response and nine disease stabilization (34, 6%). After a median follow-up of 65 months, two patients are disease-free survivors. Main toxicity was leucocytopenia grade 3/4 in 30% of the patients. Conclusion: Combination chemotherapy with oxaliplatin and paclitaxel is feasible with acceptable toxicity and may be effective if combined with additional treatment in patients with CDDP-refractory GCT. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
47. The postchemotherapy PSA surge syndrome.
- Author
-
R. Thuret, C. Massard, M. Gross-Goupil, B. Escudier, M. Di Palma, A. Bossi, R. de Crevoisier, A. Chauchereau, and K. Fizazi
- Subjects
- *
DRUG therapy , *PROSTATE cancer , *CANCER patients , *CANCER treatment , *PHYSICIANS - Abstract
Background: Chemotherapy has emerged as a standard treatment in patients with castration-refractory prostate cancer (CRPC). Consensus criteria are available to define response in CRPC as at least a 50% decline in serum prostate-specific antigen (PSA) confirmed 4 weeks later. The objective of this work was to study early serum PSA changes in patients under chemotherapy and to correlate these changes with subsequent response assessment. Patients and methods: Serum PSA levels were monitored every 3 weeks in 79 patients with CRPC treated with chemotherapy and a time course of serum PSA levels was obtained. Correlation with response was studied. Results: According to consensus criteria, 21 (40%) and 20 (38%) patients achieved a PSA response and stabilization, respectively, after first-line chemotherapy. Among patients who achieved either a response or a stabilization, 8 of 41 (20%) had a serum PSA rise during the first 8 weeks of chemotherapy, followed by a subsequent decline in serum PSA. The same observation was made in patients receiving second-line chemotherapy: 6 of 20 patients achieving a response or stabilization had an initial serum PSA rise. The postchemotherapy increase in serum PSA could reach more than twice the baseline value. The duration of the PSA surge ranged from 1 to 8 weeks. When considering responders only, 6 of 30 (20%) had a postchemotherapy serum PSA surge, followed by a drop. Conclusion: Postchemotherapy PSA surges occur not infrequently in patients with CRPC who respond to chemotherapy. Physicians should be aware of this effect to avoid inadequate early discontinuation of chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
48. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
- Author
-
S Culine, P Kerbrat, A Kramar, C Théodore, C Chevreau, L Geoffrois, NB Bui, J Pény, A Caty, R Delva, P Biron, K Fizazi, J Bouzy, and JP Droz
- Subjects
- *
TUMORS , *DRUG therapy , *METASTASIS , *BLEOMYCIN , *ETOPOSIDE , *CISPLATIN , *CANCER patients , *PROGNOSIS - Abstract
Background: High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin. Patients and methods: Patients received either three cycles of BE500P or four cycles of E500P every 3 weeks. Disease was defined according to the Institut Gustave Roussy prognostic model. Patients were retrospectively assigned into the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. A sample size of 250 patients was necessary for an expected favorable response rate (primary end point) of 90% and not more than a 10% difference between the two arms. Results: Among 257 assessable patients, 124 and 122 patients achieved a favorable response in the 3BE500P and 4E500P arms, respectively (P = 0.34). Median follow-up was 53 months. The 4-year event-free survival rates were 91% and 86%, respectively (P = 0.135). The 4-year overall survival rates were not significantly different [five deaths versus 12 deaths, respectively (P = 0.096)]. Similar nonsignificant trends were observed in good IGCCCG prognosis patients. Conclusions: Both regimens produced similar results in terms of favorable response rates. As the trial was underpowered for survival analyses, conclusive data would require a larger randomized trial. Unless such a study is done, 3BE500P is the treatment of choice for metastatic NSGCT patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
49. Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.
- Author
-
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S, Smith MR, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kakiuchi H, Akiyama M, Li R, Kuss I, Joensuu H, and Suzuki H
- Subjects
- Humans, Male, Aged, Japan, Middle Aged, Pyrazoles therapeutic use, Pyrazoles adverse effects, Pyrazoles administration & dosage, Aged, 80 and over, Androgen Antagonists therapeutic use, Androgen Antagonists administration & dosage, Androgen Antagonists adverse effects, Double-Blind Method, Neoplasm Metastasis, Treatment Outcome, East Asian People, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Docetaxel therapeutic use, Docetaxel administration & dosage, Docetaxel adverse effects, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Prostatic Neoplasms mortality
- Abstract
Background: In the global ARASENS study (NCT02799602), darolutamide plus androgen-deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.57-0.80; p < 0.0001), with a favorable safety profile in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We investigated outcomes in Japanese participants., Methods: Patients were randomized 1:1 to oral darolutamide 600 mg twice daily or placebo, plus ADT and docetaxel. The primary endpoint was overall survival., Results: The Japanese subgroup comprised 148 patients (darolutamide 63, placebo 85). In the Japanese versus overall population, more patients were aged ≥75 years (darolutamide/placebo 35%/22% vs. 16%/17%) and had body mass index <25 kg/m
2 (78%/79% vs. 46%/43%), The ECOG performance status 0 (92%/88% vs. 72%/71%), de novo mHSPC (95%/97% vs. 86%/87%), and Gleason score ≥8 (94%/92% vs. 78%/79%). Median treatment duration was 43.3/15.4 months for darolutamide/placebo. The overall survival HR for darolutamide versus placebo was 0.91 (95% CI 0.50-1.64), despite 85% of patients in the placebo group receiving subsequent life-prolonging therapy. Darolutamide prolonged time to castration-resistant prostate cancer (HR 0.31; 95% CI 0.17-0.55). Treatment-emergent adverse event incidences were generally similar between groups. Adverse events known to be associated with docetaxel (e.g., neutropenia) were more frequent in the Japanese versus overall population., Conclusion: In conclusion, efficacy outcomes showed positive trends for darolutamide plus ADT and docetaxel in Japanese patients with mHSPC, consistent with the overall population, despite higher risk factors. The combination was well tolerated, with no new safety signals in Japanese patients., (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
50. Multivariable models of outcomes with [ 177 Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.
- Author
-
Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, Rahbar K, Tagawa ST, Czernin J, El-Haddad G, Wong CC, Zhang Z, Wilke C, Mirante O, Morris MJ, and Fizazi K
- Abstract
Background: [
177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains a clinical challenge. We present the first multivariable models of outcomes with177 Lu-PSMA-617 built using data from VISION, a large prospective phase 3 clinical trial powered for overall survival., Methods: Adults with progressive post androgen receptor pathway inhibitor and taxane prostate-specific membrane antigen (PSMA)-positive mCRPC received177 Lu-PSMA-617 plus protocol-permitted standard of care (SoC) or SoC alone. In this post hoc analysis, multivariable Cox proportional hazards models of overall survival (OS) and radiographic progression-free survival (rPFS), and a logistic regression model of prostate-specific antigen response (≥50% decline; PSA50) were constructed and evaluated using C-index or receiver operating characteristic (ROC) analyses with bootstrapping validation. Nomograms were constructed for visualisation., Findings: Patients were randomised between June 2018 and October 2019. Data from all 551 patients in the177 Lu-PSMA-617 arm were analysed in multivariable modelling. The OS nomogram (C-index, 0.73; 95% confidence interval [CI], 0.70-0.76) included whole-body maximum standardised uptake value (SUVmax ), time since diagnosis, opioid analgesic use, aspartate aminotransferase, haemoglobin, lymphocyte count, presence of PSMA-positive lesions in lymph nodes, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and neutrophil count. The rPFS nomogram (C-index, 0.68; 0.65-0.72) included SUVmax , time since diagnosis, opioid analgesic use, lymphocyte count, presence of liver metastases by computed tomography, LDH, and ALP. The PSA50 nomogram (area under ROC curve, 0.72; 95% CI, 0.68-0.77) included SUVmax , lymphocyte count and ALP. Performances of the OS and rPFS models were maintained when they were reconstructed excluding SUVmax ., Interpretation: These models of outcomes with177 Lu-PSMA-617 are the first built using prospective phase 3 data. They show that a combination of pretreatment laboratory, clinical, and imaging parameters, reflecting both patient and tumour status, influences outcomes. These models are important for aiding treatment selection, patient management, and clinical trial design., Funding: Novartis., Competing Interests: KH reports receiving grants or contracts from Boston Scientific, Janssen, and Novartis; consulting fees from Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, Novartis, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, Theragnostics, and ymabs; and stock or other ownership in AdvanCell, Aktis Oncology, Convergent, NVision, Pharma 15, and Sofie Biosciences. JSdB reports receiving grants or contracts from Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Crescendo, Daiichi-Sankyo, Endocyte, Genentech/Roche, GlaxoSmithKline, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi Aventis; consulting or advisory fees from Astellas, AstraZeneca, Bayer, Daiichi-Sankyo, Genentech/Roche, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme, Orion, Pfizer, Sanofi Aventis, and Taiho; payment or honorarium from Astellas, AstraZeneca, Bayer, Cellcentric, Crecendo, Daiichi, Genentech, Genmab, GlaxoSmithKline, Janssen, Merck Serono, Mycrix, MSD, Orion, Pfizer, Sanofi Aventis, and Taiho; being an inventor on patent 8,822,438; participating on a data safety monitoring or advisory board for Amgen, AstraZeneca, Bayer, Bioxcel Therapeutics, Crescendo, Daiichi-Sankyo, Endocyte, Genentech/Roche, GlaxoSmithKline, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Oncternal, Pfizer, and Sanofi Aventis; and receiving institutional royalties or licenses related to abiraterone, PARP inhibitor, and PI3K/AKT. OS reports receiving support for the present manuscript from Novartis; institutional grants or contracts from Amgen, AstraZeneca, Bayer, Endocyte, Invitae, Janssen, Lantheus, Merck, Novartis, Progenics, and Tenebio; consulting fees from ARTBIO, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity Pharmaceuticals, Fusion, Isotopen Technologien Muenchen, Janssen, Merck, Myovant, Myriad, Noria Therapeutics, NorthStar, Novartis, Pfizer, POINT Biopharma, Sanofi, Telix, and Tenebio; travel and accommodation expenses from Lantheus, NorthStar, and Novartis; participation on a data safety monitoring or advisory board for AstraZeneca, Merck, and Pfizer; and stock or stock options in ARTBIO, Clarity Pharmaceuticals, Convergent, Fusion, Lilly, Pfizer, Ratio, and Telix. KNC reports receiving grants or contracts from AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, POINT Biopharma, and Roche; and consulting fees from Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, POINT Biopharma, and Roche. BJK reports receiving consultant or advisory fees from Bayer, Isotope Technologies Munich, and Novartis; and research funding from Novartis. KR reports receiving consultant fees from ABX, ABX-CRO, Amgen, Bayer Healthcare, Janssen Cilag, Novartis, and Sirtex; and lecture payments from AstraZeneca, Bayer Healthcare, Novartis, and Siemens Healthcare. STT reports receiving institutional fees from AbbVie, Ambrx, Amgen, Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Clarity, Clovis, Endocyte, Genentech, Gilead, Inovio, Janssen, Karyopharm, Medivation, Merck, Newlink, Novartis, POINT Biopharma, Rexahn, Sanofi, and Seattle Genetics; and consultant fees from AbbVie, Aikido Pharma, Ambrx, Amgen, Astellas, Bayer, Blue Earth, Clarity Pharma, Clovis, Convergent Therapeutics, Daiichi Sankyo, Eisai, EMD Serono, Genentech, Genomic Health, Janssen, Medivation, Merck, Myovant, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seattle Genetics, Telix, Tolmar, and TransThera. JC reports stock or other ownership interest in Sofie Biosciences, Inc., and Trethera; acting as an uncompensated founder for Trethera; and an uncompensated adviser for Amgen, Atkis Oncology, Jubilant Radiopharma, Novartis, POINT Biopharma, and RayzeBio. GEH reports receiving consultant fees from Bayer HealthCare, Boston Scientific Corporation, NorthStar Medical Radioisotopes, Novartis, and Terumo; and stock ownership in Johnson and Johnson. CCW reports employment and stock ownership with Novartis. ZZ reports previous employment and current stock ownership with Novartis. CW reports employment and stock ownership with Novartis. OM reports employment and stock ownership with Novartis. MJM reports receiving consulting or advisory fees from Amgen, AstraZeneca, Blue Earth Diagnostics, Clarity Pharmaceuticals, Convergent Therapeutics, Daiichi, ITM Isotope Technologies Munich, Lantheus Medical Imaging, Pfizer, POINT Biopharma, Progenics, Telix Pharmaceuticals, and Z-Alpha; stock and other ownership in Doximity; travel, accommodations, and expenses from APCCC, AstraZeneca, and Memorial Sloan-Kettering Cancer Center; institutional research funding from Astellas Pharma, Bayer, Celgene, Corcept Therapeutics, Janssen, Novartis, Progenics, and Roche/Genentech; patents pending with Novartis; and royalties from Telix. KF reports receiving institutional honorarium or payments to Gustave Roussy Institute from Astellas, AstraZeneca, Bayer, Janssen, MSD, Novartis, and Sanofi; institutional participation on data safety monitoring or advisory boards for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis, Pfizer, and Sanofi; and personal participation on a data safety monitoring or advisory board for Arvinas, CureVac, Macrogenics, Orion. No other potential conflict of interest relevant to this article was reported., (© 2024 The Authors.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.